Table 3.
Comparison of results evaluating imiquimod treatment of periocular nodular basal cell carcinoma
| First author year | N | Dosing regimen, days/week, weeks | Mean size (SD) mm | Lesions greater than 10 mm (%) | Complete response (%) | Follow-up (years) | Histological follow-up (months) |
|---|---|---|---|---|---|---|---|
| Present study | 19 | 5/wk | 11.1 (6.0) | 58 | 84.2 | 3.3 | 36 |
| 8–16 wk | |||||||
| Prokosch 2011 [11] | 4 | 5/wk | 11.5 (4.5) | 50 | 100 | 7.0 | - |
| 6 wk | |||||||
| Garcia-Martin 2010 [13] | 15 | 5/wk | 7.6 (2.9) | 25 | 100 | 2.0 | 3 |
| 6 wk | |||||||
| Carneiro 2010 [22] | 10 | 5/wk | 12.1 (6.5) | 60 | 80 | 1.0 | 12 |
| 10–16 wk | |||||||
| Choontanom 2007 [10] | 5 | 5/wk | 10.8 (4.2) | 40 | 80 | 3.0 | - |
| 6 wk | |||||||
| Leppälä 2007 [12] | 4 | 5/wk | 8.5 (4.6) | 25 | 100 | 0.5 | 3 |
| 6 wk | |||||||
| Blasi 2005 [9] | 2 | 3/wk | - | - | 100 | 1.0 | - |
| 8–12 wk |
SD = standard deviation; wk = weeks.